1. Home
  2. PCYO vs BDSX Comparison

PCYO vs BDSX Comparison

Compare PCYO & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pure Cycle Corporation

PCYO

Pure Cycle Corporation

N/A

Current Price

$11.86

Market Cap

267.7M

Sector

Utilities

ML Signal

N/A

Logo Biodesix Inc.

BDSX

Biodesix Inc.

N/A

Current Price

$7.58

Market Cap

62.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCYO
BDSX
Founded
1976
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Precision Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.7M
62.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PCYO
BDSX
Price
$11.86
$7.58
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
47.9K
63.1K
Earning Date
01-07-2026
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
12.50
N/A
EPS
0.54
N/A
Revenue
$26,087,000.00
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
N/A
$25.05
P/E Ratio
$22.11
N/A
Revenue Growth
N/A
22.29
52 Week Low
$9.65
$3.44
52 Week High
$14.09
$32.20

Technical Indicators

Market Signals
Indicator
PCYO
BDSX
Relative Strength Index (RSI) 61.92 49.14
Support Level $11.61 $7.77
Resistance Level $12.12 $8.38
Average True Range (ATR) 0.34 0.55
MACD 0.05 -0.05
Stochastic Oscillator 74.68 24.49

Price Performance

Historical Comparison
PCYO
BDSX

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: